Connect with us
European Gaming Congress 2024

Artificial Intelligence

Mohawk Group Reports First Quarter 2020 Results – Net Revenue Grew 43.6% to $25.6 Million; April Net Revenue Grew 75% From Continued Ecommerce Acceleration

Published

on

Raises Net Revenue Guidance for Full Year 2020 
Expects Positive Adjusted EBITDA in the Third & Fourth Quarters of 2020
NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) — Mohawk Group Holdings, Inc. (NASDAQ: MWK) (“Mohawk”) today announced results for the first quarter ended March 31, 2020. First Quarter Highlights16 new products launched in the first quarter of 2020.First quarter net revenue grew 43.6% year over year to $25.6 million compared to $17.8 million in the first quarter of 2019.First quarter gross margin improved to 40.2% versus 37.4% in the first quarter of 2019.First quarter operating loss of $(13.9) million increased from $(7.1) million in the first quarter of 2019.First quarter contribution margin improved to (2.9%) from (4.5%) in the first quarter of 2019, reflecting both higher sustain revenues and margin expansion.Excluding non-cash stock-based compensation of $7.4 million, fixed operating expenses for the first quarter remained essentially flat.First quarter net loss of $(15.0) million increased from $(8.4) million in the first quarter of 2019.First quarter Adjusted EBITDA of $(6.4) million versus $(5.6) million in the first quarter of 2019.New COO, Pramod K C, appointed to lead Operations based out of Shenzhen officeYaniv Sarig, Co-Founder and Chief Executive Officer, commented, “As we navigate the current environment, our thoughts are with the healthcare professionals, first responders and other essential workers around the world on the frontlines of the global COVID-19 pandemic. I am so proud of the resiliency of our team members and business partners who have gone above and beyond to ensure our business and operations are running smoothly to meet the heightened needs of online consumers during these unprecedented times.”Mr. Sarig continued, “Our strong first quarter results are reflective of our ability to continue leveraging our tech enabled business model driven by data, automation and artificial intelligence to expand our market share. Importantly, as consumers are spending more time at home, we are experiencing an increase in demand for our products across categories. Balancing liquidity and growth remains a top priority, and we are managing all expenses, working capital and capital expenditures efficiently. These efforts, combined with our AIMEE software, and new product pipeline, have us well positioned to capitalize as purchasing behavior further shifts towards ecommerce.”Outlook
For full year 2020, the Company increases its net revenue expectation to be in the range of $165.0 million to $175.0 million driven primarily by continued growth of its existing product portfolio and the positive contribution from new products launched in 2020. The Company expects to generate positive Adjusted EBITDA for the three months ended September 30, 2020 and also for the three months ended December 31, 2020.
Appointment of New COOThe Company announced today the appointment of Pramod K C as Chief Operating Officer, effective June 1, 2020.  Mr. K C will oversee operations of the Company’s Asia supply chain and will be based in the Company’s Shenzhen offices. In conjunction with this announcement, the Company also announced that Peter Datos will step down from his position as Chief Operating Officer and depart the Company.Yaniv Sarig, Co-Founder and Chief Executive Officer of Mohawk Group, stated, “We are very pleased to welcome Pramod to Mohawk Group. He is a seasoned leader with significant integrated supply chain management and quality control experience in Asia, working with several well-known companies during his career. We believe his strong track record in operational management will be a great addition to our executive team. This strategic decision to shift the COO role to China highlights our increased focus on optimizing our supply chain and our commitment to accelerating the number of products we can launch while maintaining high quality and competitive pricing.”Mr. Sarig continued, “I want to thank Pete for his many contributions, especially in helping us grow our product portfolio. Pete is an accomplished leader and we wish him the best in his future endeavors.”Prior to joining the Company, Mr. K C was head of Asia Operations for G-Lab GmbH, a Swiss consumer electronics company, since April 2014. Mr. K C previously held various General Manager positions at PassageMaker Solutions, a supply chain management company in Asia, from July 2007 to March 2014 and was involved in development, procurement, production management, quality control and export logistics within the supply chain for a variety of clients, including Hewlett-Packard, DELL, Harley Davidson and Home Depot. Mr. K C started his career as a product development engineer, performing embedded software programming for consumer electronics products. He then began handling and managing integrated supply chains and operations for companies operating in the Asia-Pacific region. He holds a Bachelor in Engineering with a focus in Applied Electronics Technology from Shanghai University.Non-GAAP Financial MeasuresFor more information on our non-GAAP financial measures and a reconciliation of GAAP to non-GAAP measures, please see the “Non-GAAP Financial Measures and Reconciliations” section below.Mohawk will host a live conference call to discuss financial results today, May 11, 2020, at 5:00 p.m. Eastern Time. Investors and analysts interested in participating in the call are invited to dial (877) 295-1077 (domestic) or (470) 495-9485 (international) at 5:00 p.m. ET and provide the Conference ID: 7123909. The conference call will also be available to interested parties through a live webcast https://ir.mohawkgp.com/investor-relations. Please visit the website at least 15 minutes prior to the start of the call to register and download any necessary software.About Mohawk Group Holdings, Inc.
Mohawk Group Holdings, Inc. and subsidiaries (“Mohawk”) is a rapidly growing technology-enabled consumer products company that uses machine learning, natural language processing, and data analytics to design, develop, market and sell products. Mohawk predominantly operates through online retail channels such as Amazon and Walmart. Mohawk has six owned and operated brands: hOmeLabs, Vremi, Xtava, RIF6, Holonix Health, and Aussie Health Co. Mohawk sells products in multiple categories, including home and kitchen appliances, kitchenware, environmental appliances (i.e., dehumidifiers and air conditioners), beauty related products and, to a lesser extent, consumer electronics. Mohawk was founded on the premise that if a company selling consumer packaged goods was founded today, it would apply artificial intelligence and machine learning, the synthesis of massive quantities of data and the use of social proof to validate high caliber product offerings as opposed to over-reliance on brand value and other traditional marketing tactics.
Forward Looking StatementsAll statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements including, in particular, the statements about our expected 2020 net revenue and Adjusted EBITDA, the statements pertaining to our expected April 2020 net revenue which is subject to review by our external auditors in connection with the filing of our Form 10-Q for the period ended June 30, 2020, our ability to manage expenses, working capital and capital expenditures efficiently, our business model and our technology platform, including our ability to disrupt the consumer products industry, our ability to grow market share in existing and new product categories; and our ability to generate profitability and shareholder value. These forward-looking statements are based on management’s current expectations and beliefs and are subject to uncertainties and factors, all of which are difficult to predict and many of which are beyond our control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to, those related to the impact of COVID-19 including on consumer demand, our cash flows, financial condition and revenue growth rate; our supply chain, sourcing, manufacturing, warehousing and fulfillment; international tariffs and trade measures; inventory management, product liability claims, recalls or other safety concerns, reliance on third party online marketplaces, seasonal and quarterly variations in our revenue; acquisitions of other companies and technologies and other factors discussed in the “Risk Factors” section of our most recent periodic reports filed with the Securities and Exchange Commission (“SEC”), all of which you may obtain for free on the SEC’s website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise. We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.Investor Contacts:
Ilya Grozovsky, Mohawk Group
[email protected]
917-905-1699
Brendon Frey, ICR
[email protected]
203-682-8200
Media Contact:
Jessica Liddell, ICR
203-682-8200
[email protected]


MOHAWK GROUP HOLDINGS, INC.Condensed Consolidated Statements of Operations
(Unaudited)
(in thousands, except share and per share data)


MOHAWK GROUP HOLDINGS, INC.
Condensed Consolidated Balance Sheets
(Unaudited) (in thousands, except share and per share data)


MOHAWK GROUP HOLDINGS, INC.
Condensed Consolidated Statements of Cash Flows
(Unaudited) (in thousands)


Non-GAAP Financial Measures and ReconciliationsIn addition to disclosing financial measures prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), the press release and accompanying tables include certain non-GAAP financial measures. The non-GAAP financial measures contained herein are a supplement to the corresponding financial measures prepared in accordance with U.S. GAAP. The non-GAAP financial measures presented exclude the items described below. Management believes that adjustments for these items assist investors in making comparisons of period-to-period operating results. Furthermore, management also believes that these items are not indicative of the Company’s on-going core operating performance. These non-GAAP financial measures have certain limitations in that they do not reflect all of the costs associated with the operations of the Company’s business as determined in accordance with GAAP.Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. The non-GAAP financial measures presented by the Company may be different from the non-GAAP financial measures used by other companies.The Company has presented the following non-GAAP measures to assist investors in understanding the Company’s core net operating results on an on-going basis: (i) Contribution margin; (ii) Contribution margin as a percentage of net revenue; (iii) Adjusted EBITDA; and (iv) Adjusted EBITDA as a percentage of net revenue and (v) cash burn. These non-GAAP financial measures may also assist investors in making comparisons of the Company’s core operating results with those of other companies.As used herein, Contribution margin represents operating loss plus general and administrative expenses, research and development expenses and fixed sales and distribution expenses including stock-based compensation. As used herein, Contribution margin as a percentage of net revenue represents Contribution margin divided by net revenue. As used herein, EBITDA represents net loss plus depreciation and amortization, interest expense, net and income tax expense. As used herein, Adjusted EBITDA represents EBITDA plus stock-based compensation expense and other expense, net.  As used herein, Adjusted EBITDA as a percentage of net revenue represents Adjusted EBITDA divided by net revenue. Contribution margin, EBITDA and Adjusted EBITDA do not represent and should not be considered as alternatives to loss from operations or net loss, as determined under GAAP.We present Contribution margin, Contribution margin as a percentage of net revenue, EBITDA, Adjusted EBITDA and Adjusted EBITDA as a percentage of net revenue because we believe each of these measures provides an additional metric to evaluate our operations and, when considered with both our GAAP results and the reconciliation to net loss, provides useful supplemental information for investors. We use Contribution margin, Contribution margin as a percentage of net revenue, EBITDA, Adjusted EBITDA and Adjusted EBITDA as a percentage of net revenue, together with financial measures prepared in accordance with GAAP, such as sales and gross margins, to assess our historical and prospective operating performance, to provide meaningful comparisons of operating performance across periods, to enhance our understanding of our operating performance and to compare our performance to that of our peers and competitors.We believe EBITDA, Adjusted EBITDA and Adjusted EBITDA as a percentage of net revenue are useful to investors in assessing the operating performance of our business without the effect of non-cash items, while Contribution margin and Contribution margin as a percentage of net revenue are useful to investors in assessing the operating performance of our products as they represent our operating results without the effects of fixed costs and non-cash items.  Contribution margin, Contribution margin as a percentage of net revenue, EBITDA, Adjusted EBITDA and Adjusted EBITDA as a percentage of net revenue, should not be considered in isolation or as alternatives to net loss, loss from operations or any other measure of financial performance calculated and prescribed in accordance with GAAP. Neither EBITDA, Adjusted EBITDA nor Adjusted EBITDA as a percentage of net revenue should be considered a measure of discretionary cash available to us to invest in the growth of our business. Our Contribution margin, Contribution margin as a percentage of net revenue, EBITDA, Adjusted EBITDA and Adjusted EBITDA as a percentage of net revenue may not be comparable to similar titled measures in other organizations because other organizations may not calculate Contribution margin, EBITDA, Adjusted EBITDA or Adjusted EBITDA as a percentage of net revenue in the same manner as we do. Our presentation of Contribution margin and Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by the expenses that are excluded from such terms or by unusual or non-recurring items.We recognize that both EBITDA, Adjusted EBITDA and Adjusted EBITDA as a percentage of net revenue, have limitations as analytical financial measures. For example, neither EBITDA nor Adjusted EBITDA reflects:our capital expenditures or future requirements for capital expenditures or mergers and acquisitions;the interest expense or the cash requirements necessary to service interest expense or principal payments, associated with indebtedness;depreciation and amortization, which are non-cash charges, although the assets being depreciated and amortized will likely have to be replaced in the future, or any cash requirements for the replacement of assets; orchanges in cash requirements for our working capital needs.Additionally, Adjusted EBITDA excludes non-cash expense for stock-based compensation, which is and will remain a key element of our overall long-term incentive compensation package.The following table represents a reconciliation of EBITDA and Adjusted EBITDA to net loss, which is the most directly comparable financial measure presented in accordance with GAAP (in thousands):We also recognize that Contribution margin and Contribution margin as a percentage of net revenue have limitations as analytical financial measures. For example, Contribution margin does not reflect:general and administrative expenses necessary to operate our business;research and development expenses necessary for the development, operation and support of our software platform; orthe fixed costs portion of our sales and distribution expenses including stock-based compensation expenseThe following table provides a reconciliation of Contribution Margin to operating loss, which is the most directly comparable financial measure presented in accordance with GAAP (in thousands):  We believe each of our products goes through three core phases as follows:Launch phase: During this phase, we leverage our technology to target opportunities identified using AIMEE. During this period of time, and due to the combination of discounts and investment in marketing, our net margin for a product could be as low as negative 35%. In general, a product may stay in the launch phase on average for 3 months.Sustain phase: Our goal is for every product we launch to enter the sustain phase and become profitable, with a target average of positive 10% net margin (i.e. contribution margin). Over time, our products benefit from economies of scale stemming from purchasing power both with manufacturers and with fulfillment providers.Liquidate phase: If a product does not enter the sustain phase or if the customer satisfaction of the product (i.e., ratings) are not satisfactory, then it will go to the liquidate phase and we will sell the remaining inventory.The following table breaks out our quarterly results of operations by our product phases including our SaaS business line:
As used herein, cash burn represents the change of the net change in cash balance at each of the balance sheet periods adjusted for certain one-time items like the initial public offering and excluding changes in restricted cash. We use cash burn to provide an additional metric to evaluate our cash flows from our business operations. We believe cash burn is useful to investors to evaluate the cash operating performance of our business without the effect of certain one-time items (i.e., the initial public offering).   Our method for calculating cash burn may not be used by other organizations and therefore our cash burn amount may not be directly comparable to the cash burn disclosed by other organizations. The following table provides a reconciliation of cash burn to the net change in cash and restricted cash for period, which is the most directly comparable financial measure presented in accordance with GAAP:

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Northern Data Group is first in Europe to acquire NVIDIA H200 GPUs

Published

on

northern-data-group-is-first-in-europe-to-acquire-nvidia-h200-gpus

First in Europe to acquire NVIDIA H200 GPUs – currently the most powerful GPUs on the market The deployment further expands the Group’s Generative AI CSP offering, already the largest in Europe Further demonstration of the Group’s continued commitment to providing best-in-class technologies FRANKFURT, Germany, July 1, 2024 /PRNewswire/ — Northern Data Group (Ticker symbol German stock market: NB2, ISIN: DE000A0SMU87), a leading provider of High-Performance Computing (HPC) solutions, today announces it has purchased NVIDIA H200 GPUs through a newly established partnership with Supermicro, a global leader in Application-Optimized Total IT Solutions.

Northern Data Group’s cloud platform, Taiga Cloud will be the first Cloud Service Provider (CSP) in Europe to offer access to the H200 GPU hardware, with delivery and deployment scheduled for Q4 2024. The partnership with Supermicro for the NVIDIA H200 GPUs will further build its HPC solutions and complement its existing offering of best-in-class GenAI technologies.
This purchase of the H200 GPUs demonstrates Northern Data Group’s commitment to offering the best-in-class technology to its customers, as it continues to expand its cloud solutions offering, while also maintaining its position as Europe’s first and largest dedicated Generative AI Cloud Service Provider.
The first full island of over 2,000 NVIDIA H200 GPUs utilizing BlueField-3 data processing units (DPUs) and NVIDIA Mellanox CX7 NICs, to deliver 32 petaFLOPS of performance. The configuration of NVIDIA-referenced architecture allows customers to access more bandwidth, faster, and more efficient data storage access. The H200 GPUs will be housed in one of Northern Data Group’s European data centers, powered by carbon-free, renewable energy and boast a Power Usage Effectiveness ratio of less than 1.2.
Aroosh Thillainathan, Founder and CEO, Northern Data Group, commented:
“Our GenAI platform is constantly evolving and we are proud to collaborate with Supermicro to be the first in Europe to offer access to NVIDIA H200 GPUs. This is testament to our commitment to continually offer industry-leading, next-generation solutions. 
“As an Elite Partner of NVIDIA, we are proud to continue to offer cutting-edge technology, deployed in line with recommended architecture references to maximize the technology.” 
Vik Malyala, President & Managing Director, EMEA; SVP, Technology & AI, Supermicro commented:
“We are excited to collaborate with Northern Data Group to expand its GenAI Cloud offering to include Supermicro GPU servers based on latest Nvidia H200 HGX GPUs.  Supermicro is fully committed to delivering most performant and energy efficient AI infrastructure and solutions, and this collaboration will accelerate availability and bring the best value for customers in Europe.”
About Northern Data Group: 
Northern Data Group (ETR: NB2) is a leading provider of High-Performance Computing (HPC) solutions to businesses and research institutions, utilizing GPU- and ASIC-based solutions. Our flexible compute power fuels innovation in our three core business platforms: Taiga Cloud, Ardent Data Centers, and Peak Mining. Through our HPC solutions, we pioneer ambitious computing innovation that drives progress in the AI, ML and Generative AI industries. Our close collaboration with industry-leading manufacturers including Gigabyte, AMD, and NVIDIA is fundamental to the acceleration of innovation across sectors including life sciences, financial services, and energy. 
About Taiga Cloud:
Taiga Cloud, a Northern Data Group platform, is Europe’s first and largest Generative AI Cloud Service Provider. We provide a flexible, secure and compliant cloud-based ultra-fast GPU Network, engineered to meet organizations’ most ambitious compute needs. Taiga Cloud recognizes that high-intensity, large-scale processing power is crucial for accelerating Generative AI models and research which will deliver a new era of technological breakthroughs. Taiga’s energy-efficient Cloud is powered by Europe’s largest cluster of NVIDIA A100 Tensor Core and H100 Tensor Core GPUs, helping enable organizations to accelerate AI and ML innovation on demand, with technology that is fully scalable.

View original content:https://www.prnewswire.co.uk/news-releases/northern-data-group-is-first-in-europe-to-acquire-nvidia-h200-gpus-302185926.html

Continue Reading

Artificial Intelligence

Dawn Health and Merck are collaborating to support Growth Disorders care

Published

on

dawn-health-and-merck-are-collaborating-to-support-growth-disorders-care

COPENHAGEN, Denmark, July 1, 2024 /PRNewswire/ — Dawn Health, the digital health company pioneering patient-first innovation, has announced they are working with leading global pharmaceutical company, Merck, on a digital solution for Growth Hormone Disorders (GHD).

Over the next two years, they will join forces to deliver a cutting-edge, user-centric digital platform, designed to help improve the lives of tens of thousands of patients across more than 40 countries.
By harnessing the latest AI technologies, the collaboration will also involve exploring the integration of features such as growth predictions and advanced personalization into the digital product, with excitement about AI and its potential for impact on user experience, adoption, adherence, and treatment outcomes. The digital solution will provide support to children and young adults living with GHD, as well as providing tools and support to their caregivers, both at home and in a clinical setting. 
With a shared commitment to improving patient lives, the collaboration will focus on patient-centricity to deliver an intuitive, engaging product that supports users and caregivers throughout their treatment journey. This means speaking with patients to truly understand their unmet needs and how the solution can best address these, as well as hearing from caregivers and healthcare professionals about how to best empower and support those living with GHD.
The collaboration is already off to a strong start, with workshops and inspiring discussions happening between the teams at Dawn Health and Merck, as they work together to deliver a cutting-edge platform on a global scale to improve the lives of people living with Growth Hormone Disorders.
About Merck
Merck, a leading science and technology company, operates across life science, healthcare and electronics. Around 63,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2023, Merck generated sales of € 21 billion in 65 countries. Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.
All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
About Dawn Health
Dawn Health is a global leader in digital health, specializing in the development of software as a medical device (SaMD) and digital therapeutics (DTx). Partnering with pharmaceutical companies, Dawn Health accelerates the launch of digital solutions to change the lives of people with chronic conditions.
Media Contacts
For questions about [email protected] 
For questions about Dawn HealthChristopher Kold, [email protected]
 

View original content:https://www.prnewswire.co.uk/news-releases/dawn-health-and-merck-are-collaborating-to-support-growth-disorders-care-302184356.html

Continue Reading

Artificial Intelligence

Transforming Healthcare with AI: Yidu Tech’s Gong Rujing at Summer Davos

Published

on

transforming-healthcare-with-ai:-yidu-tech’s-gong-rujing-at-summer-davos

DALIAN, China, July 1, 2024 /PRNewswire/ — “AI in healthcare is extremely challenging. For companies, it requires not only solving scientific problems but also understanding AI technology and respecting the complexity of the healthcare industry.” At the 15th Annual Meeting of the New Champions, also known as Summer Davos, Ms. Gong Rujing (Yingying), Chairwoman and Founder of Yidu Tech, was invited as a distinguished representative of the healthcare technology sector. She shared her unique insights into the future of AI in healthcare during the thematic dialogue on “Healthcare Analytics, Not Moving Fast Enough.”

This year marks the 10th anniversary of Yidu Tech and Ms. Gong Rujing’s decade-long dedication to the healthcare industry. From the inception of her entrepreneurial journey 10 years ago, she has been driven by the mission to leverage the power of technology to deliver precise healthcare to every individual.
Ms. Gong described the past decade as a journey filled with miracles and achievements. During this period, Yidu Tech has progressively established close collaborations with key stakeholders in the healthcare industry, including government agencies, hospitals, pharmaceutical companies, insurance firms, experts, and clinicians. As of March 31, 2024, Yidu Tech’s “AI Medical Brain” YiduCore has been authorized to process and analyze over 5 billion medical records, covering more than 2,500 hospitals.
In AI-powered clinical research, Yidu Tech has supported researchers and clinicians in producing over 240 high-level papers, accelerating the application of research outcomes. Additionally, Yidu Tech provides clinical trial services to globally renowned pharmaceutical companies, helping them optimize trial processes, reduce costs, and bring new drugs to market more swiftly, ultimately benefiting patients. In healthcare management, Yidu Tech’s AI technology plays a crucial role by analyzing vast amounts of medical data to provide comprehensive decision support to healthcare administrators, helping them optimize resource allocation and improve service efficiency.
“We are now entering a new era of AI technology.” The development of large language model technologies has opened up new possibilities across various industries. Yidu Tech has independently developed a large language model specific to the medical field and is advancing its application across the entire healthcare industry chain. The goal is to promote further progress and innovation through new AI technologies. However, Ms. Gong also emphasized that the healthcare industry is professional, complex, and sensitive, and the application of new technologies must address challenges such as data security, privacy protection, and ethics.
“Data security and privacy protection are fundamental to the development of AI technology and medical big data technology. We must ensure that all stakeholders are satisfied with compliance, security, accessibility, and privacy protection.”
“AI technology still has a long way to go.” She called on policymakers, healthcare institutions, and technology companies to work together to realize the immense potential of healthcare data. Ms. Gong highlighted that building trust is key, and enhancing data operability is essential to fully unleash the power of data. “It’s not just about better data quality; it’s about a better future for health.”

View original content:https://www.prnewswire.co.uk/news-releases/transforming-healthcare-with-ai-yidu-techs-gong-rujing-at-summer-davos-302186561.html

Continue Reading

Trending